Imugene (ASX: IMU) has been granted a key patent for its Fowl Adenoviral Delivery Vector in Japan. The Fowl Adenoviral Delivery Vector is the basis of all Imugene’s poultry vaccines including one of the company’s lead products, the Poultry Productivity Enhancer and the Avian Influenza Vaccine. Imugene Managing Director, Dr Warwick Lamb commented, “The grant of this key patent is very significant because Japan is a key high value market for our products. Japanese patents have also historically set strong patent precedents in other Asian countries. "Imugene has retained the right to sell the Poultry Productivity Enhancer in Australia, New Zealand and Japan and this patent completes patent coverage over these territories. Further granting of the Fowl Adenoviral Delivery Vector patent throughout Asia will strengthen commercial protection of Imugene’s pending Avian Influenza Vaccine”. END
IMU Price at posting:
0.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)